<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Cefpodoxime: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Cefpodoxime: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Cefpodoxime: Drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_patient" data-topicid="11871" href="/d/html/11871.html" rel="external">see "Cefpodoxime: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="13132" href="/d/html/13132.html" rel="external">see "Cefpodoxime: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F147808"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antibiotic, Cephalosporin (Third Generation)</li></ul></div>
<div class="block doa drugH1Div" id="F147776"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bbd52e21-dcfe-472c-a480-3587971723ab">Chronic obstructive pulmonary disease, acute exacerbation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic obstructive pulmonary disease, acute exacerbation:</b>
<b>Note: </b>Avoid use in patients with risk factors for <i>Pseudomonas</i> infection or poor outcomes (eg, ≥65 years of age with major comorbidities, FEV<sub>1</sub> &lt;50% predicted, frequent exacerbations) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Sethi.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Sethi.2022'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 200 mg twice daily for 5 to 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-GOLD.2019','lexi-content-ref-8222793']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-GOLD.2019','lexi-content-ref-8222793'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d31b3c05-03cb-4fcd-8932-e9d1953c0ab8">Odontogenic soft tissue infection, pyogenic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Odontogenic soft tissue infection, pyogenic (initial therapy for mild infection or step-down therapy after parenteral treatment) (alternative agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>For patients unable to take penicillin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Chow.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Chow.2019'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 400 mg twice daily in combination with metronidazole; continue until clinical resolution, typically for 7 to 14 days. Use in addition to appropriate surgical management (eg, drainage and/or extraction) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Chow.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Chow.2019'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a96b8104-65d0-48ba-b460-4308464e6db6">Otitis media, acute</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Otitis media, acute (alternative agent for patients with penicillin allergy that does not preclude cephalosporin use):</b>
<b>Oral:</b> 200 mg twice daily. Duration is 5 to 7 days for mild to moderate infection and 10 days for severe infection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Limb.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Limb.2021'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ae7a1cf7-80fc-4d1d-9ece-3f02289932d6">Pneumonia, community-acquired, outpatient empiric therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pneumonia, community-acquired, outpatient empiric therapy (alternative agent):</b>
<b>Oral:</b> 200 mg twice daily as part of an appropriate combination regimen. Duration of therapy is for a minimum of 5 days; patients should be clinically stable with normal vital signs before therapy is discontinued (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31573350']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31573350'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1437b55a-5145-4c15-bba4-c28709c37109">Rhinosinusitis, acute bacterial</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Rhinosinusitis, acute bacterial (alternative agent for patients with penicillin allergy who are able to tolerate cephalosporins):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> In uncomplicated acute bacterial rhinosinusitis, initial observation and symptom management without antibiotic therapy is appropriate in most patients. Reserve antibiotic therapy for poor follow-up or lack of improvement over the observation period (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25832968','lexi-content-ref-26785402']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25832968','lexi-content-ref-26785402'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 200 mg twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8539546']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8539546'])">Ref</a></span>) with clindamycin for 5 to 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22438350']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22438350'])">Ref</a></span>); some experts use as monotherapy when the risk of drug-resistant <i>S. pneumoniae</i> is low (eg, &lt;65 years of age, low endemic resistance, few comorbidities, no recent hospitalization or antibiotic use) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17292580','lexi-content-ref-Patel.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17292580','lexi-content-ref-Patel.2021'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5fe294fd-4626-4e48-9579-84675accedc8">Skin and soft tissue infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Skin and soft tissue infection (alternative agent):</b>
<b>Oral:</b> 400 mg every 12 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8467623']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8467623'])">Ref</a></span>) for 7 to 14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24947530','lexi-content-ref-8467623']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24947530','lexi-content-ref-8467623'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="47f1db45-3ef1-4229-9b6c-df5d9de732de">Streptococcal pharyngitis, group A</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Streptococcal pharyngitis, group A (alternative agent for mild, nonanaphylactic penicillin allergy):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Cephalosporin selection depends on the type of hypersensitivity reaction to penicillin. To avoid the development of resistance, narrower spectrum cephalosporins (eg, cephalexin or cefadroxil) are preferred when possible (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23091044','lexi-content-ref-Pichichero.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23091044','lexi-content-ref-Pichichero.2021'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 100 mg twice daily for 5 to 10 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17908614','lexi-content-ref-Pichichero.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17908614','lexi-content-ref-Pichichero.2021'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5ac615e6-688a-461c-8a9f-5e7703d06ac9">Urinary tract infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Urinary tract infection (alternative agent): Note:</b> Use only when preferred agents cannot be used; limited evidence suggests inferior efficacy of oral beta-lactams (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hooten.2021b','lexi-content-ref-Hooten.2021c','lexi-content-ref-21292654']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hooten.2021b','lexi-content-ref-Hooten.2021c','lexi-content-ref-21292654'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Cystitis, acute uncomplicated or acute simple cystitis (infection limited to the bladder without signs/symptoms of upper tract, prostate, or systemic infection):</i>
<b>Oral:</b> 100 mg twice daily for 5 to 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hooten.2021b','lexi-content-ref-Hooten.2021c','lexi-content-ref-22318279','lexi-content-ref-21292654','lexi-content-ref-12604518']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hooten.2021b','lexi-content-ref-Hooten.2021c','lexi-content-ref-22318279','lexi-content-ref-21292654','lexi-content-ref-12604518'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Urinary tract infection, complicated (including pyelonephritis) (off-label use):</i>
<b>Oral: </b>200 mg twice daily for 10 to 14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21292654','lexi-content-ref-29298155']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21292654','lexi-content-ref-29298155'])">Ref</a></span>); for patients with symptomatic improvement within the first 48 to 72 hours of therapy, some experts recommend shorter courses of 7 to 10 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hooten.2021a','lexi-content-ref-30535100']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hooten.2021a','lexi-content-ref-30535100'])">Ref</a></span>). <b>Note: </b>Oral beta-lactam therapy should generally follow appropriate parenteral therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hooten.2021a','lexi-content-ref-21292654']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hooten.2021a','lexi-content-ref-21292654'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991213"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b></p>
<p style="text-indent:-2em;margin-left:4em;">CrCl ≥30 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;30 mL/minute: Administer usual recommended dose every 24 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Dialyzable (~50%) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1474165','lexi-content-ref-2365467']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1474165','lexi-content-ref-2365467'])">Ref</a></span>): 100 to 200 mg every 24 hours; when scheduled dose falls on a dialysis day, administer after hemodialysis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2365467','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2365467','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Negligible clearance (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8109931']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8109931'])">Ref</a></span>): 100 to 200 mg every 24 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8109931','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8109931','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Recommendations are based on high-flux dialyzers and effluent flow rates of 20 to 25 mL/kg/hour (or ~1,500 to 3,000 mL/hour), unless otherwise noted. Close monitoring of response and adverse reactions due to drug accumulation is important.</p>
<p style="text-indent:-2em;margin-left:4em;">Dose as for CrCl ≥30 mL/minute, although use of an IV antimicrobial agent is generally preferred (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Appropriate dosing requires consideration of adequate drug concentrations (eg, site of infection) and consideration of initial loading doses. Close monitoring of response and adverse reactions due to drug accumulation is important.</p>
<p style="text-indent:-2em;margin-left:4em;">Dose as for CrCl ≥30 mL/minute, although use of an IV antimicrobial agent is generally preferred. Administer one of the twice-daily doses after PIRRT on PIRRT treatment days when possible (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988418"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">Cirrhosis (with or without ascites): No dosage adjustment necessary.</p></div>
<div class="block doe drugH1Div" id="F147777"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F147795"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="13132" href="/d/html/13132.html" rel="external">see "Cefpodoxime: Pediatric drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>General dosing: </b>Infants, Children, and Adolescents: Oral: 5 mg/kg/dose every 12 hours; usual maximum dose: 200 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bradley.2021','lexi-content-ref-AAP.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bradley.2021','lexi-content-ref-AAP.2021'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="81d31ea9-ba0c-495f-b52b-c01125f63b2b">Chronic bronchitis, bacterial exacerbation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic bronchitis, bacterial exacerbation:</b> Children ≥12 years and Adolescents: Oral: 200 mg every 12 hours for 10 days.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3ab65aa5-1c14-484a-8cfb-f1fe4746f705">Irinotecan-associated diarrhea, prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Irinotecan-associated diarrhea, prophylaxis:</b> Limited data available: Children ≥2 years and Adolescents: Oral: 5 mg/kg/dose every 12 hours; maximum dose: 200 mg/dose; begin 1 to 2 days before each treatment cycle and continue until 2 days following the last irinotecan dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21509928','lexi-content-ref-20405511']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21509928','lexi-content-ref-20405511'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a96b8104-65d0-48ba-b460-4308464e6db6">Otitis media, acute</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Otitis media, acute</b>
<b> (AOM) (alternative agent for nonanaphylactic penicillin allergy):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥2 months and Children: Oral: 5 mg/kg/dose every 12 hours; maximum dose: 200 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23439909','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23439909','lexi-content-ref-Manu.1'])">Ref</a></span>). For patients with severe or recurrent AOM, tympanic membrane perforation, or who are &lt;2 years of age, treat for 10 days; for patients ≥2 years of age with mild to moderate, nonrecurrent disease without tympanic membrane perforation, shorter durations of 5 to 7 days may be sufficient (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23439909','lexi-content-ref-28002709','lexi-content-ref-20824827','lexi-content-ref-31876601','lexi-content-ref-NICE.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23439909','lexi-content-ref-28002709','lexi-content-ref-20824827','lexi-content-ref-31876601','lexi-content-ref-NICE.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ed599b2f-52de-47cd-b7d2-d706008b1db0">Pneumonia, community-acquired</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pneumonia, community-acquired (alternative agent):</b>
<b>Note:</b> Cefpodoxime is not active against most strains of penicillin-resistant <i>Streptococcus pneumoniae</i>, and activity against penicillin-intermediate strains is variable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17943330','lexi-content-ref-18467242','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17943330','lexi-content-ref-18467242','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants &gt;3 months and Children &lt;12 years: Limited data available: Oral: 5 mg/kg/dose every 12 hours; maximum dose: 200 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7792126','lexi-content-ref-15226561']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7792126','lexi-content-ref-15226561'])">Ref</a></span>). <b> Note: </b>The usual total duration of therapy for uncomplicated pneumonia is 5 to 10 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21880587','lexi-content-ref-33683325','lexi-content-ref-32525203']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21880587','lexi-content-ref-33683325','lexi-content-ref-32525203'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years and Adolescents: Oral: 200 mg every 12 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12501878','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12501878','lexi-content-ref-Manu.1'])">Ref</a></span>). <b>Note:</b> Although the manufacturer recommends treatment duration of 14 days, the usual total duration of therapy for uncomplicated pneumonia is 5 to 10 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21880587','lexi-content-ref-33683325','lexi-content-ref-32525203']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21880587','lexi-content-ref-33683325','lexi-content-ref-32525203'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1437b55a-5145-4c15-bba4-c28709c37109">Rhinosinusitis, acute bacterial</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Rhinosinusitis, acute bacterial (alternative agent for patients with penicillin allergy): Note:</b> The role of cefpodoxime in the management of acute bacterial sinusitis is limited; other options may be preferred (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22438350']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22438350'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥2 months and Children &lt;12 years: Oral: 5 mg/kg/dose every 12 hours for 10 days; maximum dose: 200 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22438350','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22438350','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years and Adolescents: Oral: 200 mg every 12 hours for 10 days.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5fe294fd-4626-4e48-9579-84675accedc8">Skin and soft tissue infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Skin and soft tissue infection:</b>
<b> Note:</b> Cefpodoxime is not currently recommended in IDSA guidelines for treatment of skin and soft tissue infection; alternate agents are preferred (eg, first-generation cephalosporins). Additionally, durations shorter than 7 days (eg, 5 days) may be appropriate for uncomplicated infections (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24947530']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24947530'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years and Adolescents: Oral: 400 mg every 12 hours for 7 to 14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="002747a1-d12d-413d-9efb-492e8da1743e">Streptococcus, group A; pharyngitis/tonsillitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Streptococcus, group A; pharyngitis/tonsillitis (alternative agent for nonanaphylactic penicillin allergy): </b>
<b>Note:</b> Narrow-spectrum cephalosporins (eg, cephalexin) are preferred over broad-spectrum cephalosporins such as cefpodoxime (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23091044']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23091044'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥2 months, Children, and Adolescents: Oral: 5 mg/kg/dose every 12 hours; maximum dose: 100 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8483620','lexi-content-ref-7921095','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8483620','lexi-content-ref-7921095','lexi-content-ref-Manu.1'])">Ref</a></span>). Preferred treatment duration is 10 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23091044']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23091044'])">Ref</a></span>), although 5 days may be adequate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7921095','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7921095','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5ac615e6-688a-461c-8a9f-5e7703d06ac9">Urinary tract infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Urinary tract infection:</b>
<b>Note: </b>Duration of therapy should be individualized based on patient age, severity/extent of infection, and clinical response; typical duration is 7 to 14 days, though it may be as short as 5 days (eg, for uncomplicated cystitis in patients ≥2 years of age) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31958969','lexi-content-ref-29292282','lexi-content-ref-25477258']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31958969','lexi-content-ref-29292282','lexi-content-ref-25477258'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants and Children &lt;12 years: Limited data available: Oral: 4 to 5 mg/kg/dose every 12 hours; maximum dose: 200 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25477258']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25477258'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years and Adolescents: Oral: 100 to 200 mg every 12 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25477258','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25477258','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51084349"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b> Infants ≥2 months, Children, and Adolescents: Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl ≥30 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;30 mL/minute/1.73 m<sup>2</sup>: Administer usual recommended dose every 24 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis:</b> Dialyzable based on adult data (~50%) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1474165','lexi-content-ref-2365467']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1474165','lexi-content-ref-2365467'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: Oral: The manufacturer recommends administration of dose 3 times weekly after hemodialysis.</p></div>
<div class="block dohp drugH1Div" id="F51084350"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Cirrhosis (with or without ascites): Infants ≥2 months, Children, and Adolescents: No dosage adjustment necessary.</p></div>
<div class="block adr drugH1Div" id="F147739"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">&gt;10%: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Dermatologic: Diaper rash (12%) </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Gastrointestinal: Diarrhea (infants and toddlers 15%) </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">1% to 10%: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Central nervous system: Headache (1%) </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Dermatologic: Skin rash (1%) </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Gastrointestinal: Diarrhea (7%), nausea (4%), abdominal pain (2%), vomiting (1% to 2%) </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Genitourinary: Vaginal infection (3%) </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">&lt;1%: Anaphylaxis, anxiety, chest pain, cough, decreased appetite, dizziness, dysgeusia, epistaxis, eye pruritus, fatigue, fever, flatulence, flushing, fungal skin infection, hypotension, insomnia, malaise, nightmares, pruritus, pseudomembranous colitis, purpuric nephritis, tinnitus, vulvovaginal candidiasis, weakness, xerostomia </p></div>
<div class="block coi drugH1Div" id="F147754"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;margin-left:0em;display:inline">Hypersensitivity to cefpodoxime, any component of the formulation, or other cephalosporins.</p></div>
<div class="block war drugH1Div" id="F147736"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Beta-lactam allergy: Use with caution in patients with a history of beta-lactam allergy, especially IgE-mediated reactions (eg, anaphylaxis, angioedema, urticaria).</p>
<p style="text-indent:-2em;margin-left:4em;">• Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment; modify dosage in severe impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer’s labeling.</p></div>
<div class="block foc drugH1Div" id="F147748"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension Reconstituted, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 mg/5 mL (50 mL, 100 mL); 100 mg/5 mL (50 mL, 100 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mg, 200 mg</p></div>
<div class="block geq drugH1Div" id="F147732"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F147756"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension (reconstituted)</b> (Cefpodoxime Proxetil Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg/5 mL (per mL): $0.86 - $0.91</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg/5 mL (per mL): $1.72</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Cefpodoxime Proxetil Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $6.74</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg (per each): $8.43 - $8.46</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F802618"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> Administer around-the-clock to promote less variation in peak and trough serum levels. Administer tablets with food; suspension may be administered without regard to food. Shake suspension well before using.</p></div>
<div class="block admp drugH1Div" id="F52612384"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral:</p>
<p style="text-indent:-2em;margin-left:2em;">Suspension: May administer with or without food; shake suspension well before use.</p>
<p style="text-indent:-2em;margin-left:2em;">Tablet: Administer with food.</p></div>
<div class="block use drugH1Div" id="F147751"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic obstructive pulmonary disease, acute exacerbation:</b> Treatment of acute bacterial exacerbation of chronic obstructive pulmonary disease caused by <i>Streptococcus pneumoniae</i>, <i>Haemophilus influenzae</i> (non-beta-lactamase-producing strains only), or <i>Moraxella catarrhalis</i>.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Cystitis, acute uncomplicated:</b> Treatment of acute uncomplicated cystitis caused by <i>Escherichia coli</i>, <i>Klebsiella pneumoniae</i>, <i>Proteus mirabilis</i>, or <i>Staphylococcus saprophyticus</i>.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Otitis media, acute:</b> Treatment of acute otitis media caused by <i>S. pneumoniae</i> (excluding penicillin-resistant strains),<i> Streptococcus pyogenes</i>, <i>H. influenzae</i> (including beta-lactamase-producing strains), or <i>M. catarrhalis</i> (including beta-lactamase-producing strains).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Pneumonia, community-acquired:</b> Treatment of community-acquired pneumonia caused by <i>S. pneumoniae</i> or <i>H. influenzae</i> (including beta-lactamase-producing strains).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Rhinosinusitis, acute bacterial:</b> Treatment of acute bacterial rhinosinusitis caused by <i>H. influenzae</i> (including beta-lactamase-producing strains), <i>S. pneumoniae</i>, and <i>M. catarrhalis</i>. <b>Note:</b> According to the Infectious Diseases Society of America guidelines for acute bacterial rhinosinusitis, cefpodoxime is recommended in combination with clindamycin due to concern for pneumococcal resistance (IDSA [Chow 2012]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Skin and soft tissue infection: </b>Treatment of uncomplicated skin and soft tissue infection caused by <i>Staphylococcus aureus</i> (including penicillinase-producing strains) or <i>S. pyogenes</i>.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Streptococcal pharyngitis, group A</b>
<b>:</b> Treatment of pharyngitis or tonsillitis caused by <i>S. pyogenes</i>.</p></div>
<div class="block off-label drugH1Div" id="F51263223"><span class="drugH1">Use: Off-Label: Adult</span><p>Odontogenic soft tissue infection, pyogenic; Urinary tract infection, complicated (including pyelonephritis)</p></div>
<div class="block mst drugH1Div" id="F147815"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Vantin may be confused with Ventolin</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13298993"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of OAT1/3</p></div>
<div class="block dri drugH1Div" id="F147741"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Aminoglycosides: Cephalosporins may enhance the nephrotoxic effect of Aminoglycosides. Cephalosporins may decrease the serum concentration of Aminoglycosides. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antacids: May decrease the serum concentration of Cefpodoxime.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bacillus clausii: Antibiotics may diminish the therapeutic effect of Bacillus clausii.  Management: Bacillus clausii should be taken in between antibiotic doses during concomitant therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine.  Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Oral): May diminish the therapeutic effect of Antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Rectal): Antibiotics may diminish the therapeutic effect of Fecal Microbiota (Live) (Rectal). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Furosemide: May enhance the nephrotoxic effect of Cephalosporins.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Histamine H2 Receptor Antagonists: May decrease the serum concentration of Cefpodoxime.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Antibiotics may diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inhibitors of the Proton Pump (PPIs and PCABs): May decrease the serum concentration of Cefpodoxime.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Probenecid: May increase the serum concentration of Cephalosporins.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Avoid use of live attenuated typhoid vaccine (Ty21a)  in patients being treated with systemic antibacterial agents. Postpone vaccination until 3 days after cessation of antibiotics and avoid starting antibiotics within 3 days of last vaccine dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Cephalosporins may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>
<div class="block foi drugH1Div" id="F147767"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Food increases extent of absorption and peak concentration of tablets. Management: Take tablets with food.</p></div>
<div class="block pri drugH1Div" id="F5951646"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Adverse events were not observed in animal reproduction studies.</p></div>
<div class="block brc drugH1Div" id="F147757"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Cefpodoxime is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Due to the potential for serious adverse reactions in the breastfed infant, the manufacturer recommends a decision be made to discontinue breastfeeding or to discontinue the drug, taking into account the importance of treatment to the mother.</p>
<p style="text-indent:-2em;margin-left:2em;">In general, antibiotics that are present in breast milk may cause non-dose-related modification of bowel flora (WHO 2002).</p></div>
<div class="block dic drugH1Div" id="F147758"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Take tablets with food.</p></div>
<div class="block mop drugH1Div" id="F147746"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline"> Monitor renal function. Observe for signs and symptoms of anaphylaxis during first dose.</p></div>
<div class="block pha drugH1Div" id="F147735"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs) which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested.</p></div>
<div class="block phk drugH1Div" id="F147753"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Rapid and well absorbed (50%); tablet AUC increased 21% to 33% with food.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Good tissue penetration, including lung and tonsils; penetrates into pleural fluid.</p>
<p style="text-indent:-2em;margin-left:4em;">V<sub>d</sub>:</p>
<p style="text-indent:-2em;margin-left:6em;">Children &lt;5 years: 1.52 ± 0.56 L/kg (Kearns 1994).</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥5 years and Adolescents: 0.89 ± 0.3 L/kg (Kearns 1994).</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: Serum: 22% to 33%; Plasma: 21% to 29%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: De-esterified in GI tract to active metabolite, cefpodoxime.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Oral: 50%.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Children: 1.7 to 3.3 hours (Fulton 2001).</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: 2.09 to 2.84 hours; prolonged with renal impairment (~10 hours for CrCl &lt;30 mL/minute).</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: Tablets: Within 2 to 3 hours; Oral suspension: Within 2 to 3 hours; slower in presence of food, 48% increase in T<sub>max</sub>.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (~29% to 33% as unchanged drug in 12 hours).</p></div>
<div class="block phksp drugH1Div" id="F51192716"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Elimination is reduced in those with CrCl &lt;50 mL/minute.</p>
<p style="text-indent:-2em;margin-left:2em;">Pediatric: Although only 29% to 33% of the drug is excreted unchanged in the urine at 12 hours, in children 6 to 10 years, a single dose of 10 mg/kg results in urine concentrations at 4 hours ranging from 220 to 340 mg/L and at 8 hours ranging from 130 to 180 mg/L (Casellas 1993).</p>
<p style="text-indent:-2em;margin-left:2em;">Older adult: The half-life is increased to ~4.2 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Anti-infective considerations:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Parameters associated with efficacy:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Time-dependent; associated with time free drug concentration (<i>f</i>T) &gt; minimum inhibitory concentration (MIC):</p>
<p style="text-indent:-2em;margin-left:8em;">Enterobacterales: Goal: 30% to 40% <i>f</i>T &gt; MIC (bacteriostatic), 60% to 70% <i>f</i>T &gt; MIC (bactericidal) (Craig 1998; Turnidge 1998).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Streptococcus spp. </i>and <i>H. influenzae: </i>Goal: &gt;40% <i>f</i>T &gt; MIC (Craig 1998; Turnidge 1998).</p>
<p style="text-indent:-2em;margin-left:6em;">Expected drug concentration in normal renal function:</p>
<p style="text-indent:-2em;margin-left:8em;">Infants &gt;8 months of age and children ≤12 years of age, C<sub>max</sub> (peak):</p>
<p style="text-indent:-2em;margin-left:10em;">5 mg/kg, oral suspension, single dose: 2.1 mg/L.</p>
<p style="text-indent:-2em;margin-left:8em;">Adults, C<sub>max</sub> (peak):</p>
<p style="text-indent:-2em;margin-left:10em;">100 mg, oral suspension, single dose: 1.5 mg/L (range: 1.1 to 2.1 mg/L).</p>
<p style="text-indent:-2em;margin-left:10em;">100 mg, oral tablet, steady state: 1.19 ± 0.41 mg/L (Borin 1991).</p>
<p style="text-indent:-2em;margin-left:10em;">200 mg, oral tablet, steady state: 2.3 ± 0.71 mg/L (Borin 1991).</p>
<p style="text-indent:-2em;margin-left:10em;">400 mg, oral tablet, steady state: 3.62 ± 0.62 mg/L (Borin 1991).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Postantibiotic effect:</i> Generally &lt;1 hour; varies based on organism (Craig 1991; Craig 1998).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F147759"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Auropodox | Cefodox | Cefpo | Cepodem | Orelox | Podocip | Zakon</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Biocef | Cefpodoxim sandoz | Otreon</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Cefdox | Cefipod | Cefobid | Cefodim | Cefomin | Cefoprox | Ceforan | Cepdoxim | Cp | Desbac | Dofixim | Dxproxil | Epoxim | Evedoxim | Instina | Kidcef | Metoxim | Pedicef | Podoxi | Proctil | Sarelox | Sefox | Starin | Taxetil | Toraxim | Trucef | Vanprox | Vercef | Victorin | Ximeprox | Zedoxim</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Orelox</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Foxero | Sefpotec | Ximebac</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Cefpodoxima proxetil | Orelox</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Cefpodoxim sandoz | Orelox | Podomexef</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Cacef | Medfic | Melpro | Necpod | Orelox | Swich | Trizef</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Baxemin | Cefirax | Pluricef</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Banan | Bo man xin | Bo na | Cepodem | Chun di | Chun xin | Hai ling yi | Heng ze | Jia bo | Min xin | Shan pu lan | Shi bo | Shuai fu | Si li neng | Si li tai | Tao te | Wei jie xin | Xi bo te xin | Yan zhi</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Doxcef</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Forexo | Orelox</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Cefpo | Cefpodoxim 1 A Pharma | Cefpodoxim al | Cefpodoxim aurobindo | Cefpodoxim Beta | Cefpodoxim CT | Cefpodoxim Dura | Cefpodoxim Hexal | Cefpodoxim hormosan | Cefpodoxim Ratiopharm | Cefpodoxim stada | Orelox | Podomexef</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Cefopox | Orelox</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Cefirax</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Aiadoxime | Cefoprox | Cepodem | Orelox | Podacef | Spectrodoxime | Thirgecef</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Cefpodoxima aurobindo | Cefpodoxima Sandoz | Instana | Otreon</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Cefodox | Cefpodoxime</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Orelox</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Cefpodoxime Actavis | Cefpodoxime Almus | Cefpodoxime Arrow | Cefpodoxime biogaran | Cefpodoxime Cristers | Cefpodoxime EG | Cefpodoxime evolugen | Cefpodoxime Isomed | Cefpodoxime Mylan | Cefpodoxime qualimed | Cefpodoxime Ranbaxy | Cefpodoxime ratiopharm | Cefpodoxime Sandoz | Cefpodoxime Teva | Cefpodoxime Zydus | Orelox</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Cefpodoxime | Orelox</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Orebus | Orelox</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Banan | Cp | Monocef o</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Rexocef</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Orelox</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Banadoz | Banan</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Cefodox</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Akpod | Alpoxime | Altipod | Ancepod | Atack | Avicef o | Axone o | Bacotil | Bactogard | Balpod | Banin | Baroxime | Belpro | Brotacef | C Pod | Cacef | Ccl | Ce meri | Cebest | Cedon | Cedopil | Cedoxime | Cefacore | Cefakind-p | Cefantib | Cefaz | Cefbil | Cefdee | Cefdolife | Cefdom | Cefective | Cefentod | Cefjoy | Cefnova | Cefocare | Cefoclox | Cefodem | Cefoder | Cefogud | Cefopen | Cefoprox | Cefowin o | Cefpet | Cefpo | Cefpocom | Cefpolar | Cefponet | Cefpopen | Cefstrong | Ceftis | Ceftisa | Ceftocid o | Cefwar | Cepfor | Cepime-O | Cepocef | Cepocor | Cepodem | Cepotil | Cepotuf | Cepotus | Cepowin | Cepoxin | Cepy o | Cipona | Cisma | Cliver | Codimol | Compod | Cpd | Crapod | Cumin | Cupal | Delpocure | Dioxim | Dopoxime | Doxant | Doxcef | Doxderm | Doxpro | Drodox | Edox dt | Efibact | Eficef ds | Elicef | Elpicef | Elpod | Expodox | Fabupod | Fasst | Finecef | Foloup | Grandcef | Greatcef | Gudcef | Healtab | Hhcepo | Hincedox | Ibipod | Inpodox | Ipod | Kefdox | Kefmax | Kefmed | Kefodime | Kefpod | Kefprox | Kepodil | Keptil | Lezone | Libadex | Macpod | Mahapod | Mapdox | Masterpod | Mdpod | Metoxim | Microcef | Micropod | Monocef o | Monotax-o | Montego | Mpod | Nkounter | Novadox | Novodoxim | Nupod | Opox | Oxipod | P Fixim | Pandox | Pdx | Pecef | Pedi cef | Pedoxin | Phodoxime | Podcef | Podiem | Podo | Podobact | Podobid | Podocef | Podopil | Podoriv | Podox | Podoxim | Podxetil | Polares | Polypod | Poxivio | Procef | Procep | Prodox | Prodoxime | Proxil | Proxit | Proxtl | Pucef | Pyricep | Q Tax O | Rekounter | Reopod | Rispod | Safecefo | Safodex | Sedan | Sefdo | Sefdok | Spectratil | Stercef | Succidox | Suprapod | Svpod | Swich | Syprox | Tambac | Tespod | Timebond | Tixor o | Travecef | Tufpod | Umoxim | Unipod | Vegapod | Xofdim | Xop | Zedocef | Zefira | Zefpod | Zepodox | Zerapod | Zextil | Zipod | Zoypod</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Cefodox | Cefpodoxima Sandoz | Orelox | Otreon | Proxedox</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Auropodox | Cefodox | Cefpo | Metoxim | Podecif</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Banan | Banan sankyo | Sepoxym | Vanacefan</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Auropodox | Cacef | Cefaz | Cefmox | Cefoprox | Cefpo | Cefpodox | Cefpowel | Cepodem | Cepom | Cepotil | Cpodox | Cpodox ds | Dapodox | Monocef o | Nefiadox | Nepodox | Orelox | Oxipod | Podoxal | Poxil | Swich | Tambac | Virdox | Virdox ds | Ximeprox</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Anti cef | Banan | C doxime | Cedoxime | Cefadoxime | Cefanan | Cefba | Cefdoxime | Cefosime | Cefpo | Cefroxtil | Cefuny | Cenan | Cepodoxime | Cepoxetil | Cepoxim | Ceroctil | Cexime | Dongkoo cefpodoxime proxetil | Doxetil | Fadoxim | Focedin | Frondoxime | Froxtil | Huxetil | Inno.n cefpodoxime proxetil | Kofxime | Kyongbo cefpodoxime proxetil | Lofixime | Newcedox | Newcepo | Podox | Podoxef | Podoxetil | Protil | Vantin | Zalrotil</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Cefodox | Orelox</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Cefodox | Cefpodoxime arrow lab | Cepodem | Oraluxe | Orelox</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Orelox</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Orelox</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Cefaid | Cefdoxim | Cepodem | Errdon cefpodoxime | Kamalox | Mospodox | Mplon | Orelox | Tambac</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Orelox</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Cefirax</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Banan | Cebarc | Cefadox | Cefdotab | Cefpodoxime | Nefidoxime | S foxime | Swich | Trizef | Zudem</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Abacus | Baroxime | Belpro | Buticef | Carelox | Cefidox | Cefolox | Cefpo | Cefpomed | Cefporite | Cefprox | Celidoxim | Cepodox | Cobtec | Denlox | Ds saydoxim | Evodoxim | Expodox | Kp dox | Mazfed | Neudoxine | Orelox | Oribro | Oribro plus | Orid | Ornate | Oxdope | Podoxim | Prelox | Prodogin | Proxit | Qink | Rti cef | Solodoxim | Spira xime | Supralox | Vantin | Volvez | Xipodox | Zedox</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Orelox</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Vantin</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Cefirax</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Auropodox | Cefodox | Cefpo | Orelox</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Forexo</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Cefpotek | Doxcef</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Cefodox | Orelox</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Orelox</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Forexo | Orelox</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Banan</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Cefodox | Orelox</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Cruter | Dokselin | Infex | Orelox | Podora | Sefpodo | Sefpotec | Sefsidal | Seftech | Texef</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Banan</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Auropodox | Cedoxime | Cefma | Cefpotek | Cepodem | Doxcef | Pecef</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Auropodox | Cacef | Cacef 200 | Cefodox | Cepovex | Necpod | Orelox | Swich | Tambac | Toxxet</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Atoz | Buclapoxime | Dinpocef | Goldasmo | Kefodox | Markime | Orazime | Praycide</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Aspen cefpodoxime | Cepodem | Dyna cefpodoxime | Orelox | Oropod | Sandoz cefpodoxime | Simayla cefpodoxim</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Cepodem | Cepotil | Monocef o | Tambac</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Cepodem</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-31958969">
<a name="31958969"></a>Afolabi TM, Goodlet KJ, Fairman KA. Association of antibiotic treatment duration with recurrence of uncomplicated urinary tract infection in pediatric patients. <i>Ann Pharmacother</i>. 2020;54(8):757-766. doi:10.1177/1060028019900650<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefpodoxime-drug-information/abstract-text/31958969/pubmed" id="31958969" target="_blank">31958969</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefpodoxime-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bradley.2021">
<a name="Bradley.2021"></a>Alphabetical listing of antimicrobials. In: Bradley JS, Nelson JD, Barnett ED, et al, eds. <i>Nelson's Pediatric Microbial Therapy</i>. 27th ed. American Academy of Pediatrics; 2021: chap 18.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AAP.2021">
<a name="AAP.2021"></a>American Academy of Pediatrics (AAP). In: Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH, eds. <i>Red Book: 2021-2024 Report of the Committee on Infectious Diseases</i>. 32nd ed. American Academy of Pediatrics; 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29292282">
<a name="29292282"></a>Balighian E, Burke M. Urinary tract infections in children. <i>Pediatr Rev</i>. 2018;39(1):3-12. doi:10.1542/pir.2017-0007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefpodoxime-drug-information/abstract-text/29292282/pubmed" id="29292282" target="_blank">29292282</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1474165">
<a name="1474165"></a>Borin MT, Hughes GS, Kelloway JS, Shapiro BE, Halstenson CE. Disposition of cefpodoxime proxetil in hemodialysis patients. <i>J Clin Pharmacol</i>. 1992;32(11):1038-1044. doi:10.1002/j.1552-4604.1992.tb03808.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefpodoxime-drug-information/abstract-text/1474165/pubmed" id="1474165" target="_blank">1474165</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1761737">
<a name="1761737"></a>Borin MT, Hughes GS, Patel RK, Royer ME, Cathcart KS. Pharmacokinetic and tolerance studies of cefpodoxime after single- and multiple-dose oral administration of cefpodoxime proxetil. <i>J Clin Pharmacol.</i> 1991;31(12):1137-1145. doi:10.1002/j.1552-4604.1991.tb03686.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefpodoxime-drug-information/abstract-text/1761737/pubmed" id="1761737" target="_blank">1761737</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21880587">
<a name="21880587"></a>Bradley JS, Byington CL, Shah SS, et al. “The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America”, <i>Clin Infect Dis</i>, 2011, 53(7):e25-76.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefpodoxime-drug-information/abstract-text/21880587/pubmed" id="21880587" target="_blank">21880587</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8233640">
<a name="8233640"></a>Casellas JM, Tome G, Exeni R, Grimoldi I, Goldberg M, Farinati AE. Serum and urinary cefpodoxime levels and time killing curves performed in the urine of children presenting urinary tract infections. <i>Pathol Biol (Paris)</i>. 1993;41(4):385-391.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefpodoxime-drug-information/abstract-text/8233640/pubmed" id="8233640" target="_blank">8233640</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Rising.1">
<a name="Rising.1"></a>Cefpodoxime proxetil [package insert]. Allendale, NJ: Rising Pharmaceuticals; May 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Princeton.1">
<a name="Princeton.1"></a>Cefpodoxime proxetil for oral suspension [prescribing information]. Princeton, NJ: Sandoz Inc; 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aurobindo.1">
<a name="Aurobindo.1"></a>Cefpodoxime proxetil suspension [prescribing information]. East Windsor, NJ: Aurobindo Pharma USA, Inc; October 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aurobindo.2">
<a name="Aurobindo.2"></a>Cefpodoxime proxetil tablets [prescribing information]. East Windsor, NJ: Aurobindo Pharma USA, Inc; July 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-OrchidPharma.1">
<a name="OrchidPharma.1"></a>Cefpodoxime proxetil tablets [prescribing information]. Princeton, NJ: OrchidPharma, Inc; January 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sandoz.1">
<a name="Sandoz.1"></a>Cefpodoxime proxetil tablets [prescribing information]. Princeton, NJ: Sandoz Inc; 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control and Prevention (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefpodoxime-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Chow.2019">
<a name="Chow.2019"></a>Chow AW. Complications, diagnosis, and treatment of odontogenic infections. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 9, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22438350">
<a name="22438350"></a>Chow AW, Benninger MS, Brook I, et al; Infectious Diseases Society of America. IDSA clinical practice guideline for acute bacterial rhinosinusitis in children and adults. <i>Clin Infect Dis.</i> 2012;54(8):e72-e112.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefpodoxime-drug-information/abstract-text/22438350/pubmed" id="22438350" target="_blank">22438350</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9455502">
<a name="9455502"></a>Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. <i>Clin Infect Dis.</i> 1998;26(1):1-10. doi:10.1086/516284<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefpodoxime-drug-information/abstract-text/9455502/pubmed" id="9455502" target="_blank">9455502</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Craig.1991">
<a name="Craig.1991"></a>Craig WA. The postantibiotic effect. <i>Clin Microbiology Newsletter.</i> 1991;13(16):121-124. doi:10.1016/0196-4399(91)90030-Y</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8483620">
<a name="8483620"></a>Dajani AS, Kessler SL, Mendelson R, Uden DL, Todd WM. Cefpodoxime proxetil vs. penicillin V in pediatric streptococcal pharyngitis/tonsillitis. <i>Pediatr Infect Dis J</i>. 1993;12(4):275-279. doi:10.1097/00006454-199304000-00003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefpodoxime-drug-information/abstract-text/8483620/pubmed" id="8483620" target="_blank">8483620</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17943330">
<a name="17943330"></a>Fenoll A, Giménez MJ, Robledo O, et al. Influence of penicillin/amoxicillin non-susceptibility on the activity of third-generation cephalosporins against Streptococcus pneumoniae. <i>Eur J Clin Microbiol Infect Dis</i>. 2008a;27(1):75-80. doi:10.1007/s10096-007-0402-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefpodoxime-drug-information/abstract-text/17943330/pubmed" id="17943330" target="_blank">17943330</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18467242">
<a name="18467242"></a>Fenoll A, Giménez MJ, Robledo O, et al. In vitro activity of oral cephalosporins against pediatric isolates of Streptococcus pneumoniae non-susceptible to penicillin, amoxicillin or erythromycin. <i>J Chemother</i>. 2008b;20(2):175-179. doi:10.1179/joc.2008.20.2.175<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefpodoxime-drug-information/abstract-text/18467242/pubmed" id="18467242" target="_blank">18467242</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11269640">
<a name="11269640"></a>Fulton B, Perry CM. Cefpodoxime proxetil: a review of its use in the management of bacterial infections in paediatric patients. <i>Paediatr Drugs</i>. 2001;3(2):137-158. doi:10.2165/00128072-200103020-00006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefpodoxime-drug-information/abstract-text/11269640/pubmed" id="11269640" target="_blank">11269640</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-GOLD.2019">
<a name="GOLD.2019"></a>Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: 2022 report. hhttps://goldcopd.org/wp-content/uploads/2021/12/GOLD-REPORT-2022-v1.1-22Nov2021_WMV.pdf. Accessed September 14, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hooten.2021a">
<a name="Hooten.2021a"></a>Gupta K. Acute complicated urinary tract infection (including pyelonephritis) in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 16, 2022b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hooten.2021b">
<a name="Hooten.2021b"></a>Gupta K. Acute simple cystitis in females. Post TW, ed. UpToDate<i>.</i> Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 16, 2022a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hooten.2021c">
<a name="Hooten.2021c"></a>Gupta K. Acute simple cystitis in adult males. Post TW, ed. UpToDate<i>.</i> Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 6, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21292654">
<a name="21292654"></a>Gupta K, Hooton TM, Naber KG, et al; Infectious Diseases Society of America; European Society for Microbiology and Infectious Diseases. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. <i>Clin Infect Dis</i>. 2011;52(5):e103-e120. doi: 10.1093/cid/ciq257.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefpodoxime-drug-information/abstract-text/21292654/pubmed" id="21292654" target="_blank">21292654</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17292580">
<a name="17292580"></a>Hadley JA, Pfaller MA. Oral beta-lactams in the treatment of acute bacterial rhinosinusitis. <i>Diagn Microbiol Infect Dis</i>. 2007;57(3 Suppl):S47-S54. doi:10.1016/j.diagmicrobio.2006.11.018<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefpodoxime-drug-information/abstract-text/17292580/pubmed" id="17292580" target="_blank">17292580</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26785402">
<a name="26785402"></a>Harris AM, Hicks LA, Qaseem A; High Value Care Task Force of the American College of Physicians and for the Centers for Disease Control and Prevention. Appropriate antibiotic use for acute respiratory tract infection in adults: advice for high-value care from the American College of Physicians and the Centers for Disease Control and Prevention. <i>Ann Intern Med</i>. 2016;164(6):425-434. doi: 10.7326/M15-1840.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefpodoxime-drug-information/abstract-text/26785402/pubmed" id="26785402" target="_blank">26785402</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28002709">
<a name="28002709"></a>Hoberman A, Paradise JL, Rockette HE, et al. Shortened antimicrobial treatment for acute otitis media in young children. <i>N Engl J Med</i>. 2016;375(25):2446-2456. doi:10.1056/NEJMoa1606043<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefpodoxime-drug-information/abstract-text/28002709/pubmed" id="28002709" target="_blank">28002709</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2365467">
<a name="2365467"></a>Höffler D, Koeppe P, Corcilius M, Przyklinik A. Cefpodoxime proxetil in patients with endstage renal failure on hemodialysis. <i>Infection</i>. 1990;18(3):157-162. doi:10.1007/BF01642104<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefpodoxime-drug-information/abstract-text/2365467/pubmed" id="2365467" target="_blank">2365467</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22318279">
<a name="22318279"></a>Hooton TM, Roberts PL, Stapleton AE. Cefpodoxime vs ciprofloxacin for short-course treatment of acute uncomplicated cystitis: a randomized trial. <i>JAMA.</i> 2012;307(6):583-589.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefpodoxime-drug-information/abstract-text/22318279/pubmed" id="22318279" target="_blank">22318279</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278. doi:10.1542/peds.99.2.268<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefpodoxime-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8109931">
<a name="8109931"></a>Johnson CA, Ateshkadi A, Zimmerman SW, et al. Pharmacokinetics and ex vivo susceptibility of cefpodoxime proxetil in patients receiving continuous ambulatory peritoneal dialysis. <i>Antimicrob Agents Chemother</i>. 1993;37(12):2650-2655. doi:10.1128/AAC.37.12.2650<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefpodoxime-drug-information/abstract-text/8109931/pubmed" id="8109931" target="_blank">8109931</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29298155">
<a name="29298155"></a>Johnson JR, Russo TA. Acute pyelonephritis in adults. <i>N Engl J Med</i>. 2018;378(1):48-59. doi:10.1056/nejmcp1702758<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefpodoxime-drug-information/abstract-text/29298155/pubmed" id="29298155" target="_blank">29298155</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12604518">
<a name="12604518"></a>Kavatha D, Giamarellou H, Alexiou Z, et al. Cefpodoxime-proxetil versus trimethoprim-sulfamethoxazole for short-term therapy of uncomplicated acute cystitis in women. <i>Antimicrob Agents Chemother</i>. 2003;47(3):897-900.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefpodoxime-drug-information/abstract-text/12604518/pubmed" id="12604518" target="_blank">12604518</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kearns.1994">
<a name="Kearns.1994"></a>Kearns GL, Darville T, Wells TG, Jacobs RF, Hughes GS, Borin MT. Single dose pharmacokinetics of cefpodoxime proxetil in infants and children. <i>Drug Invest</i>. 1994;7(5):221-233.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7792126">
<a name="7792126"></a>Klein M. Multicenter trial of cefpodoxime proxetil vs. amoxicillin-clavulanate in acute lower respiratory tract infections in childhood. International Study Group. <i>Pediatr Infect Dis J</i>. 1995;14(4 Suppl):S19-S22. doi:10.1097/00006454-199504001-00004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefpodoxime-drug-information/abstract-text/7792126/pubmed" id="7792126" target="_blank">7792126</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20824827">
<a name="20824827"></a>Kozyrskyj A, Klassen TP, Moffatt M, Harvey K. Short-course antibiotics for acute otitis media. <i>Cochrane Database Syst Rev</i>. 2010;2010(9):CD001095. doi:10.1002/14651858.CD001095.pub2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefpodoxime-drug-information/abstract-text/20824827/pubmed" id="20824827" target="_blank">20824827</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23439909">
<a name="23439909"></a>Lieberthal AS, Carroll AE, Chonmaitree T, et al. The diagnosis and management of acute otitis media. <i>Pediatrics</i>. 2013;131(3):e964-999.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefpodoxime-drug-information/abstract-text/23439909/pubmed" id="23439909" target="_blank">23439909</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Limb.2021">
<a name="Limb.2021"></a>Limb CJ, Lustig LR, Durand ML. Acute otitis media in adults. Post TW, ed. UpToDate<i>.</i> Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 28, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31876601">
<a name="31876601"></a>Marchisio P, Galli L, Bortone B, et al. Updated guidelines for the management of acute otitis media in children by the Italian Society of Pediatrics: treatment. <i>Pediatr Infect Dis J</i>. 2019;38(12S suppl):S10-S21. doi:10.1097/INF.0000000000002452<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefpodoxime-drug-information/abstract-text/31876601/pubmed" id="31876601" target="_blank">31876601</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21509928">
<a name="21509928"></a>McGregor LM, Stewart CF, Crews KR, et al. Dose escalation of intravenous irinotecan using oral cefpodoxime: a phase I study in pediatric patients with refractory solid tumors. <i>Pediatr Blood Cancer</i>. 2012;58(3):372-379. doi:10.1002/pbc.23075<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefpodoxime-drug-information/abstract-text/21509928/pubmed" id="21509928" target="_blank">21509928</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20405511">
<a name="20405511"></a>McNall-Knapp RY, Williams CN, Reeves EN, Heideman RL, Meyer WH. Extended phase I evaluation of vincristine, irinotecan, temozolomide, and antibiotic in children with refractory solid tumors. <i>Pediatr Blood Cancer</i>. 2010;54(7):909-915. doi:10.1002/pbc.22460<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefpodoxime-drug-information/abstract-text/20405511/pubmed" id="20405511" target="_blank">20405511</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31573350">
<a name="31573350"></a>Metlay JP, Waterer GW, Long AC, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. <i>Am J Resp Crit Care Med</i>. 2019;200(7):e45-e67. doi:10.1164/rccm.201908-1581ST.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefpodoxime-drug-information/abstract-text/31573350/pubmed" id="31573350" target="_blank">31573350</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NICE.1">
<a name="NICE.1"></a>National Institute for Health and Care Excellence (NICE). Otitis media (acute): antimicrobial prescribing. London, UK: National Institute for Health and Care Excellence. https://www.nice.org.uk/guidance/ng91. Published March 2018. Accessed November 3, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Patel.2021">
<a name="Patel.2021"></a>Patel ZM, Hwang PH. Uncomplicated acute sinusitis and rhinosinusitis in adults: treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 23, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33683325">
<a name="33683325"></a>Pernica JM, Harman S, Kam AJ, et al. Short-course antimicrobial therapy for pediatric community-acquired pneumonia: The SAFER randomized clinical trial. <i>JAMA Pediatr</i>. 2021;175(5):475-482. doi:10.1001/jamapediatrics.2020.6735<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefpodoxime-drug-information/abstract-text/33683325/pubmed" id="33683325" target="_blank">33683325</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8222793">
<a name="8222793"></a>Phillips H, Van Hook CJ, Butler T, Todd WM. A comparison of cefpodoxime proxetil and cefaclor in the treatment of acute exacerbation of COPD in adults. <i>Chest</i>. 1993;104(5):1387-1392.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefpodoxime-drug-information/abstract-text/8222793/pubmed" id="8222793" target="_blank">8222793</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Pichichero.2021">
<a name="Pichichero.2021"></a>Pichichero ME. Treatment and prevention of streptococcal pharyngitis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 1, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17908614">
<a name="17908614"></a>Pichichero ME, Casey JR. Bacterial eradication rates with shortened courses of 2nd- and 3rd-generation cephalosporins versus 10 days of penicillin for treatment of group A streptococcal tonsillopharyngitis in adults. <i>Diagn Microbiol Infect Dis</i>. 2007;59(2):127-130.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefpodoxime-drug-information/abstract-text/17908614/pubmed" id="17908614" target="_blank">17908614</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7921095">
<a name="7921095"></a>Pichichero ME, Gooch WM, Rodriguez W, et al. Effective short-course treatment of acute group A beta-hemolytic streptococcal tonsillopharyngitis. Ten days of penicillin V vs 5 days or 10 days of cefpodoxime therapy in children. <i>Arch Pediatr Adolesc Med</i>. 1994;148(10):1053-1060. doi:10.1001/archpedi.1994.02170100051010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefpodoxime-drug-information/abstract-text/7921095/pubmed" id="7921095" target="_blank">7921095</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25832968">
<a name="25832968"></a>Rosenfeld RM, Piccirillo JF, Chandrasekhar SS, et al. Clinical practice guideline (update): adult sinusitis. <i>Otolaryngol Head Neck Surg</i>. 2015;152(2)(suppl):S1-S39. doi: 10.1177/0194599815572097.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefpodoxime-drug-information/abstract-text/25832968/pubmed" id="25832968" target="_blank">25832968</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32525203">
<a name="32525203"></a>Same RG, Amoah J, Hsu AJ, et al. The association of antibiotic duration with successful treatment of community-acquired pneumonia in children. <i>J Pediatric Infect Dis Soc</i>. 2021;10(3):267-273. doi:10.1093/jpids/piaa055<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefpodoxime-drug-information/abstract-text/32525203/pubmed" id="32525203" target="_blank">32525203</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15226561">
<a name="15226561"></a>Sengupta J, Mondal AK, Jain P, Garg RD, Mathur NC, Moharana AK. Comparative evaluation of cefpodoxime versus cefixime in children with lower respiratory tract infections. <i>Indian J Pediatr</i>. 2004;71(6):517-521. doi:10.1007/BF02724293<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefpodoxime-drug-information/abstract-text/15226561/pubmed" id="15226561" target="_blank">15226561</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sethi.2022">
<a name="Sethi.2022"></a>Sethi S, Murphy TF. Management of infection in exacerbations of chronic obstructive pulmonary disease. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 16, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23091044">
<a name="23091044"></a>Shulman ST, Bisno AL, Clegg HW, et al. Clinical practice guideline for the diagnosis and management of group A streptococcal pharyngitis: 2012 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2012;55(10):1279-1282. doi:10.1093/cid/cis847<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefpodoxime-drug-information/abstract-text/23091044/pubmed" id="23091044" target="_blank">23091044</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25477258">
<a name="25477258"></a>Stein R, Dogan HS, Hoebeke P, et al. Urinary tract infections in children: EAU/ESPU guidelines. <i>Eur Urol</i>. 2015;67(3):546-558. doi:10.1016/j.eururo.2014.11.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefpodoxime-drug-information/abstract-text/25477258/pubmed" id="25477258" target="_blank">25477258</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24947530">
<a name="24947530"></a>Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2014;59(2):147-159. doi: 10.1093/cid/ciu296.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefpodoxime-drug-information/abstract-text/24947530/pubmed" id="24947530" target="_blank">24947530</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8467623">
<a name="8467623"></a>Stevens DL, Pien F, Drehobl M. Comparison of oral cefpodoxime proxetil and cefaclor in the treatment of skin and soft tissue infections. <i>Diagn</i>
<i>Microbiol Infect Dis.</i> 1993;16(2):123-129.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefpodoxime-drug-information/abstract-text/8467623/pubmed" id="8467623" target="_blank">8467623</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9675443">
<a name="9675443"></a>Turnidge JD. The pharmacodynamics of beta-lactams. <i>Clin Infect Dis.</i> 1998;27(1):10-22. doi:10.1086/514622<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefpodoxime-drug-information/abstract-text/9675443/pubmed" id="9675443" target="_blank">9675443</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12501878">
<a name="12501878"></a>van Zyl L, le Roux JG, LaFata JA, et al. Cefditoren pivoxil versus cefpodoxime proxetil for community-acquired pneumonia: results of a multicenter, prospective, randomized, double-blind study. <i>Clin Ther</i>. 2002;24(11):1840-1853. doi:10.1016/s0149-2918(02)80083-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefpodoxime-drug-information/abstract-text/12501878/pubmed" id="12501878" target="_blank">12501878</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8539546">
<a name="8539546"></a>von Sydow C, Savolainen S, Söderqvist A. Treatment of acute maxillary sinusitis--comparing cefpodoxime proxetil with amoxicillin. <i>Scand J Infect Dis</i>. 1995;27(3):229-234.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefpodoxime-drug-information/abstract-text/8539546/pubmed" id="8539546" target="_blank">8539546</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34292926">
<a name="34292926"></a>Workowski KA, Bachmann LH, Chan PA, et al. Sexually transmitted infections treatment guidelines, 2021. <i>MMWR Recomm Rep</i>. 2021;70(4):1-187. doi:10.15585/mmwr.rr7004a1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefpodoxime-drug-information/abstract-text/34292926/pubmed" id="34292926" target="_blank">34292926</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.1">
<a name="WHO.1"></a>World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. Available at http://www.who.int/maternal_child_adolescent/documents/55732/en/
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30535100">
<a name="30535100"></a>Yahav D, Franceschini E, Koppel F, et al; Bacteremia Duration Study Group. Seven versus 14 days of antibiotic therapy for uncomplicated gram-negative bacteremia: a noninferiority randomized controlled trial.<i> Clin Infect Dis</i>. 2019;69(7):1091-1098. doi:10.1093/cid/ciy1054<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefpodoxime-drug-information/abstract-text/30535100/pubmed" id="30535100" target="_blank">30535100</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9224 Version 268.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
